This is a strong clinical catalyst for GSK's oncology pipeline. The magnitude of OS benefit (54% risk reduction, 8.2-month median gain) and first-in-class B7-H3 ADC data de-risk the broader Ris-Rez program. Watch for the EMBOLD SCLC-301 pivotal readout next year and potential regulatory filings outside China. The stock may re-rate on pipeline optionality.
Drug in focus
GSK drug pipeline →risvutatug rezetecan
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- ~3-4 years for global approval; China approval possible ~12-18 months post Hansoh filing
- Next catalyst
- None dated
What to watchThe ARTEMIS-008 Phase 3 win in China (positive OS vs topotecan in SCLC) is a major validation of the B7-H3 ADC mechanism, but for GSK investors the real catalyst is the global Phase 3 readout (primary completion now Oct 2027). Watch for China NDA filing timing and any early data from the ongoing EMBOLD/ARTEMIS expansion trials in prostate, NSCLC, and other solid tumors. With ~$1-2B peak sales potential (ex-China), risvutatug rezetecan is a meaningful but non-binary asset within GSK's broader pipeline.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $50.05entry
- T+1 · 2mo ago −0.08%α +0.38% · $50.01
- T+5 · 8w ago +2.06%α +1.95% · $51.08
- T+20 · 5w ago −6.25%α −8.52% · $46.92
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in relapsed small cell lung cancer in China. Ris-Rez reduced the risk of death by 54% vs topotecan (HR 0.46, p<0.0001), with median OS of 18.5 months vs 10.3 months, and showed a favorable safety profile. This is the first Phase III data to demonstrate an OS benefit for a B7-H3 ADC in any tumor type, supporting GSK's global development program with pivotal data from the EMBOLD SCLC-301 trial expected next year.
Key Facts
- Ris-Rez reduced risk of death by 54% vs topotecan in relapsed SCLC (HR 0.46; 95% CI: 0.35-0.62, p<0.0001)
- Median OS: 18.5 months (Ris-Rez) vs 10.3 months (topotecan)
- Median PFS: 7.2 months vs 3.0 months (HR 0.33)
- Objective response rate: 58.3% vs 12.6%
- Grade 3+ TRAEs: 60.9% (Ris-Rez) vs 78.2% (topotecan)
- First Phase III data to show OS benefit for a B7-H3 ADC in any tumor type
- GSK holds ex-China rights; pivotal global data from EMBOLD SCLC-301 expected next year
Financial Impact
Positive Phase III OS data for Ris-Rez in SCLC, a high-unmet-need indication; potential peak sales could be significant but no revenue figures provided in filing
Risk Factors
- Data are from a China-only trial; global regulatory path and commercial uptake outside China are unproven
- Competitive landscape for B7-H3 ADCs is evolving with multiple developers
- Pivotal global data from EMBOLD SCLC-301 not yet available; execution risk remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008321 |
| Document: 0001654954-26-008321-index-headers.html | 0001654954-26-008321 |
| Document: 0001654954-26-008321-index.html | 0001654954-26-008321 |
| Document: 0001654954-26-008321.txt | 0001654954-26-008321 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers